

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MOTTELINI et al.

Atty. Ref.: 620-414

Serial No. 10/567,157

Group: unknown

Filed: February 3, 2006

Examiner: Unknown

For: THERAPEUTIC DELIVERY OF CARBON MONOXIDE

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

May 17, 2006

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
 B. J. Sadoff
 Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE

CITATION

ATTY. DOCKET NO.

SERIAL NO.

620-414

10/567,157

APPLICANT

MOTTELINI et al.

(Use several sheets if necessary)

FILING DATE

GROUP

February 3, 2006

unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

1	Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem. 1969;244:6388-6394.
2	Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol. 1997;37:517-554.
3	Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH. Carbon monoxide: a putative neural messenger. Science. 1993;259:381-384.
4	Sacerdoti D, Escalante B, Abraham NG, McGiff JC, Lever RD, Schwartzman ML. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science. 1989;243:388-390.
5	Marks GS, Brien JF, Nakatsu K, McLaughlin BE. Does carbon monoxide have a physiological function? Trends Pharmacol Sci. 1991;12:185-188.
6	Coceani F, Kelsey L, Seidltz E, Marks GS, McLaughlin BE, Vreman HJ, Stevenson DK, Rabinovitch M, Ackley C. Carbon monoxide formation in the ductus arteriosus in the lamb: Implications for the regulation of muscle tone. Br J Pharmacol. 1997;120:599-608.
7	Johnson RA, Colombari E, Colombari DSA, Lavesa M, Talman WT, Nasjletti A. Role of endogenous carbon monoxide in central regulation of arterial pressure. Hypertension. 1997;30:962-967.
8	Wang R, Wang ZZ, Wu LY. Carbon monoxide-induced vasorelaxation and the underlying mechanisms. Br J Pharmacol. 1997;121:927-934.
9	Motterlini R, Gonzales A, Foresti R, Clark JE, Green CJ, Winslow RM. Heme oxygenase-1-derived carbon monoxide contributes to the suppression of acute hypertensive responses in vivo. Circ Res. 1998;83:568-577.
10	Sammur IA, Foresti R, Clark JE, Exon DJ, Vesely MJ, Sarathchandra P, Green CJ, Motterlini R. Carbon monoxide is a major contributor to the regulation of vascular tone in aortas expressing high levels of haeme oxygenase-1. Br J Pharmacol. 1998;125:1437-1444.
11	Suematsu M, Goda N, Sano T, Kashiwagi S, Egawa T, Shinoda Y, Ishimura Y. Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest. 1995;96:2431-2437.
12	Morita T, Mitsialis SA, Koike H, Liu YX, Kourembanas S. Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells. J Biol Chem. 1997;272:32804-32809.
13	Sato K, Balla J, Otterbein L, Smith RN, Brouard S, Lin Y, Csizmadia E, Sevigny J, Robson SC, Vercellotti G, Choi AM, Bach FH, Soares MP. Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. J Immunol. 2001;166:4185-4194.
14	Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell RA, Choi AM. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med. 2000;6:422-8.
15	Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AM, Soares MP. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med. 2000;192:1015-1026.
16	Song R, Mahidhara RS, Liu F, Ning W, Otterbein LE, Choi AM. Carbon monoxide inhibits human airway smooth muscle cell proliferation via mitogen-activated protein kinase pathway. Am J Respir Cell Mol Biol. 2002;27:603-610.
17	Otterbein LE, Mantell LL, Choi AMK. Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol. 1999;276:L688-L694.

Examiner

/Amy Lewis/

Date Considered

09/28/2010

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-414

10/567,157

APPLICANT

MOTTELINI et al.

(Use several sheets if necessary)

FILING DATE

GROUP

February 3, 2006

unknown

FOREIGN PATENT DOCUMENTS

	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	25 WO 02/092075	11/2002	WIPO				
	41 EP 0 034 238	08/1981	Europe				
	42 WO 93/05795	04/1993	WIPO				
	43 EP 0 181 721	05/1986	Europe				
	47 WO 03/066067	08/2003	WIPO				
	48 EP 0 632 026 A	01/1995	Europe				
	49 WO 94/01413 A	01/1994	WIPO				
	50 WO 01/25243 A	04/2001	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

18	Fujita T, Toda K, Karimova A, Yan SF, Naka Y, Yet SF, Pinsky DJ. Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis. <i>Nat Med.</i> 2001;7:598-604.
19	Foresti R, Motterlini R. The heme oxygenase pathway and its interaction with nitric oxide in the control of cellular homeostasis. <i>Free Rad Res.</i> 1999;31:459-475.
20	Otterbein LE. Carbon monoxide: innovative anti-inflammatory properties of an age-old gas molecule. <i>Antioxid Redox Signal.</i> 2002;4:309-319.
21	Chauveau C, Bouchet D, Roussel JC, Mathieu P, Braudeau C, Renaudin K, Tesson L, Souillou JP, Iyer S, Buelow R, Anegón I. Gene transfer of heme oxygenase-1 and carbon monoxide delivery inhibit chronic rejection. <i>Am J Transplant.</i> 2002;2:581-592.
22	Motterlini R, Foresti R, Green CJ. Studies on the development of carbon monoxide-releasing molecules: potential applications for the treatment of cardiovascular dysfunction. In: <i>Carbon Monoxide and Cardiovascular Functions.</i> Wang R, ed. 2002. CRC Press, Boca Raton, Florida.
23	Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE, Green CJ. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. <i>Circ Res.</i> 2002;90:E17-E24.
24	Clark JE, Naughton P, Shurey S, Green CJ, Johnson TR, Mann BE, Foresti R, Motterlini R. Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule. <i>Circ Res.</i> 2003;93:e2-e8.
26	Johnson TR, Mann BE, Clark JE, Foresti R, Green CJ, Motterlini R. Metal carbonyls: a new class of pharmaceuticals? <i>Angew Chem Int Ed Engl.</i> 2003;In press.
27	Motterlini R, Mann BE, Johnson TR, Clark JE, Foresti R, Green CJ. Bioactivity and pharmacological actions of carbon monoxide-releasing molecules. <i>Curr Pharm Des.</i> 2003;In press
28	Waibel R, Alberto R, Willuda J, Finnern R, Schibli R, Stichelberger A, Egli A, Abram U, Mach JP, Pluckthun A, Schubiger PA. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. <i>Nat Biotechnol.</i> 1999;17:897-901.
29	Egli A, Alberto R, Tannahill L, Schibli R, Abram U, Schaffland A, Waibel R, Tourwe D, Jeannin L, Iterbeke K, Schubiger PA. Organometallic 99mTc-aquaion labels peptide to an unprecedented high specific activity. <i>J Nucl Med.</i> 1999;40:1913-1917.

Examiner

/Amy Lewis/

Date Considered

09/28/2010

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

